John McCamant echoes my sentiments regarding FDA approval, I cannot imagine the FDA turning down marketing approval given the history of this debacle. It would tarnish McClellan's objectives in attempting to improve approval guidelines and send the wrong message to cancer advocates, cancer patients, pharma/biotech focused on oncologic therapeutics, and pop the biotech investment faith (again).
Market Data 
Markets 
AI
